公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC classification number: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20190263784A1

公开(公告)日：2019-08-29

申请号：US16342892

申请日：2017-10-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Katsunori NAGAI ,  Takuto KOJIMA ,  Shinichi IMAMURA ,  Masao HIRAKATA

IPC: C07D401/14 ,  A61K31/6615 ,  A61K31/05 ,  A61K31/57 ,  A61K31/09 ,  A61K31/58 ,  A61P35/00 ,  A61P3/00 ,  A61K9/00

Abstract: The present invention relates to N-((3S,4R)-1-((8-chloroquinoxalin-6-yl)carbonyl)-3-(4-fluorophenyl)piperidin-4-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide, which is a compound that can be useful for the treatment or prevention of SPT-related diseases including congenital diseases associated with the storage of sphingolipids, such as cancer and Niemann-Pick disease, or a salt thereof.

公开(公告)号：US20180170874A1

公开(公告)日：2018-06-21

申请号：US15565891

申请日：2016-04-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasutomi ASANO ,  Takuto KOJIMA ,  Osamu KURASAWA ,  Tzu-Tshin WONG ,  Yasuhiro HIRATA ,  Naoki IWAMURA ,  Bunnai SAITO ,  Yuta TANAKA ,  Ryosuke ARAI ,  Shinichi IMAMURA ,  Kazuko YONEMORI ,  Yasufumi MIYAMOTO ,  Shuji KITAMURA ,  Osamu SANO

IPC: C07D211/58 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07D215/42 ,  C07D401/12 ,  C07D417/12 ,  C07D405/06 ,  C07D413/06 ,  C07D401/06 ,  C07D417/06 ,  C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07B59/00 ,  A61P35/00 ,  A61P3/00

CPC classification number: C07D211/58 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/661 ,  A61K33/22 ,  A61P3/00 ,  A61P35/00 ,  C07B59/002 ,  C07B2200/05 ,  C07D215/42 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F5/02 ,  C07F9/6509

Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

公开(公告)号：US20160376244A1

公开(公告)日：2016-12-29

申请号：US15190642

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Shinkichi SUZUKI ,  Hiroki SAKAMOTO ,  Masami YAMADA ,  Minoru NAKAMURA ,  Makoto KAMATA ,  Kenichiro SHIMOKAWA ,  Masaki OGINO ,  Eiji KIMURA ,  Masataka MURAKAMI ,  Jinichi YONEMORI ,  Takuto KOJIMA

IPC: C07D265/22 ,  C07D413/06 ,  C07D491/107 ,  C07D413/04 ,  C07F7/02 ,  C07D471/04 ,  C07D413/14 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07B2200/07 ,  C07D265/22 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02 ,  C07F7/0814

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract translation: 其中每个符号如所附的说明中所定义。

公开(公告)号：US20240217957A1

公开(公告)日：2024-07-04

申请号：US18522917

申请日：2023-11-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Asato KINA ,  Zenichi IKEDA ,  Mitsunori KONO ,  Yuya OGURO ,  Osamu KUBO ,  Toru YAMASHITA ,  Kazuaki TAKAMI ,  Takafumi YUKAWA ,  Masaki SETO ,  Makoto KAMATA ,  Kenjiro SATO ,  Masataka MURAKAMI ,  Yusuke SASAKI ,  Matthew Thomas REYNOLDS ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Takuto KOJIMA ,  Keiko KAKEGAWA ,  Florian PÜNNER ,  Shinji NAKAMURA ,  Nao MORISHITA ,  Tadashi HIDAKA ,  Sachie TAKASHIMA ,  Takahiko TANIGUCHI

IPC: C07D413/04 ,  A61P25/00 ,  C07D413/14

CPC classification number: C07D413/04 ,  A61P25/00 ,  C07D413/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20210179603A1

公开(公告)日：2021-06-17

申请号：US17176861

申请日：2021-02-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D417/12 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D413/14 ,  C07D231/14 ,  C07D333/40 ,  C07D285/08 ,  C07D285/135 ,  C07D231/12 ,  C07D277/56 ,  C07D409/14 ,  C07D413/12 ,  C07D307/81

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20170001994A1

公开(公告)日：2017-01-05

申请号：US15270863

申请日：2016-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/12 ,  C07D285/135 ,  C07D409/12 ,  C07D413/12 ,  C07D407/12 ,  C07D213/82 ,  C07D417/14 ,  C07D333/38 ,  C07D231/14 ,  C07D307/79

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US20150291577A1

公开(公告)日：2015-10-15

申请号：US14682695

申请日：2015-04-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D409/12 ,  C07D333/38 ,  C07D407/12 ,  C07D213/82 ,  C07D417/12 ,  C07D307/79

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US20240317733A1

公开(公告)日：2024-09-26

申请号：US18449326

申请日：2023-08-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubral pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula




wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20190248776A1

公开(公告)日：2019-08-15

申请号：US16394762

申请日：2019-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Shinkichi SUZUKI ,  Hiroki SAKAMOTO ,  Masami YAMADA ,  Minoru NAKAMURA ,  Makoto KAMATA ,  Kenichiro SHIMOKAWA ,  Masaki OGINO ,  Eiji KIMURA ,  Masataka MURAKAMI ,  Jinichi YONEMORI ,  Takuto KOJIMA

IPC: C07D413/14 ,  C07D491/107 ,  C07D471/04 ,  C07D417/06 ,  C07D413/10 ,  C07D413/06 ,  C07D265/22 ,  C07F7/02 ,  C07D413/04 ,  C07F7/08 ,  A61P25/28 ,  C07D417/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07B2200/07 ,  C07D265/22 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02 ,  C07F7/0814

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.